Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III MHB088C versus physician's choice chemotherapy in recurrent extensive-stage small cell lung cancer
ChiCTR2500101326Phase 3Not yet recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Apr 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of MHB088C in small cell lung cancer (SCLC) (4 arms), sponsored by Shanghai East Hospital. Primary endpoint: Overall survival. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
MHB088C
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2500101326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101326.